Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954

Biochemical Pharmacology

Volumn 79, Issue 5, 2010, Pages 678-687

  Prosser, G A ^a   Copp, J N ^a   Syddall, S P ^b,c   Williams, E M ^a   Smaill, J B ^b,c   Wilson, W R ^b,c   Patterson, A V ^b,c   Ackerley, D F ^a,c  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CB1954; GDEPT; Nitroaromatic prodrug; Nitroreductase; SOS chromotest

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; NITROREDUCTASE; PRODRUG; PROTEIN NFSA; PROTEIN NFSB; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CANCER CELL; CATALYSIS; CELL STRAIN HCT116; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME KINETICS; ESCHERICHIA COLI; GENE DELETION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN PURIFICATION; THIN LAYER CHROMATOGRAPHY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE SILENCING; GENE THERAPY; HUMANS; KINETICS; NITROREDUCTASES; PRODRUGS; SOS RESPONSE (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 72149105881     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.008     Document Type: Article

References (62)

1. Denny W.A. Nitroreductase-based GDEPT. Curr Pharm Des 8 (2002) 1349-1361
2. Cobb L.M., Connors T.A., Elson L.A., Khan A.H., Mitchley B.C., Ross W.C., et al. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem Pharmacol 18 (1969) 1519-1527
3. Knox R.J., Friedlos F., Jarman M., and Roberts J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37 (1988) 4661-4669
4. Boland M.P., Knox R.J., and Roberts J.J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 41 (1991) 867-875
5. Schlager J.J., and Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45 (1990) 403-409
6. Chen S., Knox R., Wu K., Deng P.S., Zhou D., Bianchet M.A., et al. Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse. J Biol Chem 272 (1997) 1437-1439
7. Anlezark G.M., Melton R.G., Sherwood R.F., Coles B., Friedlos F., and Knox R.J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 44 (1992) 2289-2295
8. Djeha A.H., Hulme A., Dexter M.T., Mountain A., Young L.S., Searle P.F., et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 7 (2000) 721-731
9. Lukashev A.N., Fuerer C., Chen M.J., Searle P., and Iggo R. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum Gene Ther 16 (2005) 1473-1483
10. Chung-Faye G., Palmer D., Anderson D., Clark J., Downes M., Baddeley J., et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7 (2001) 2662-2668
11. Patel P., Young J.G., Mautner V., Ashdown D., Bonney S., Pineda R.G., et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Mol Ther 17 (2009) 1292-1299
12. Anlezark G.M., Melton R.G., Sherwood R.F., Wilson W.R., Denny W.A., Palmer B.D., et al. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 50 (1995) 609-618
13. Hu L., Yu C., Jiang Y., Han J., Li Z., Browne P., et al. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J Med Chem 46 (2003) 4818-4821
14. Johnson L., Shen A., Boyle L., Kunich J., Pandey K., Lemmon M., et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1 (2002) 325-337
15. Lemmon M.J., van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 4 (1997) 791-796
16. Race P.R., Lovering A.L., White S.A., Grove J.I., Searle P.F., Wrighton C.W., et al. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. J Mol Biol 368 (2007) 481-492
17. Guise C.P., Grove J.I., Hyde E.I., and Searle P.F. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle. Gene Ther 14 (2007) 690-698
18. Jarrom D., Jaberipour M., Guise C.P., Daff S., White S.A., Searle P.F., et al. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954. Biochemistry 48 (2009) 7665-7672
19. Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L, et al. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochem Pharmacol, 2009 [E-pub online; doi:10.1016/j.bcp.2009.07.025].
20. Emptage C.D., Knox R.J., Danson M.J., and Hough D.W. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation. Biochem Pharmacol 77 (2009) 21-29
21. Theys J., Pennington O., Dubois L., Anlezark G., Vaughan T., Mengesha A., et al. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 95 (2006) 1212-1219
22. Anlezark G.M., Vaughan T., Fashola-Stone E., Michael N.P., Murdoch H., Sims M.A., et al. Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. Microbiology 148 (2002) 297-306
23. Barak Y., Thorne S.H., Ackerley D.F., Lynch S.V., Contag C.H., and Matin A. New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. Mol Cancer Ther 5 (2006) 97-103
24. Berne C., Betancor L., Luckarift H.R., and Spain J.C. Application of a microfluidic reactor for screening cancer prodrug activation using silica-immobilized nitrobenzene nitroreductase. Biomacromolecules 7 (2006) 2631-2636
25. Vass S.O., Jarrom D., Wilson W.R., Hyde E.I., and Searle P.F. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954. Br J Cancer 100 (2009) 1903-1911
26. French C.E., Nicklin S., and Bruce N.C. Sequence and properties of pentaerythritol tetranitrate reductase from Enterobacter cloacae PB2. J Bacteriol 178 (1996) 6623-6627
27. Liu G., Zhou J., Lv H., Xiang X., Wang J., Zhou M., et al. Azoreductase from Rhodobacter sphaeroides AS1.1737 is a flavodoxin that also functions as nitroreductase and flavin mononucleotide reductase. Appl Microbiol Biotechnol 76 (2007) 1271-1279
28. Leitsch D., Kolarich D., Binder M., Stadlmann J., Altmann F., and Duchene M. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol 72 (2009) 518-536
29. Tavares A.F., Nobre L.S., Melo A.M., and Saraiva L.M. A novel nitroreductase of Staphylococcus aureus with S-nitrosoglutathione reductase activity. J Bacteriol 191 (2009) 3403-3406
30. Ackerley D.F., Barak Y., Lynch S.V., Curtin J., and Matin A. Effect of chromate stress on Escherichia coli K-12. J Bacteriol 188 (2006) 3371-3381
31. Quillardet P., Huisman O., D'Ari R., and Hofnung M. SOS chromotest, a direct assay of induction of an SOS function in Escherichia coli K-12 to measure genotoxicity. Proc Natl Acad Sci USA 79 (1982) 5971-5975
32. Shapiro E., and Baneyx F. Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection. Antimicrob Agents Chemother 46 (2002) 2490-2497
33. Datsenko K.A., and Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97 (2000) 6640-6645
34. 2. J Biol Chem 280 (2005) 22590-22595
35. Alksne L.E., Burgio P., Hu W., Feld B., Singh M.P., Tuckman M., et al. Identification and analysis of bacterial protein secretion inhibitors utilizing a SecA-LacZ reporter fusion system. Antimicrob Agents Chemother 44 (2000) 1418-1427
36. Miller J.H. Experiments in molecular genetics (1972), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY p. 466
37. Ackerley D.F., Gonzalez C.F., Keyhan M., Blake II R., and Matin A. Mechanism of chromate reduction by the Escherichia coli protein, NfsA, and the role of different chromate reductases in minimizing oxidative stress during chromate reduction. Environ Microbiol 6 (2004) 851-860
38. Hobbs S., Jitrapakdee S., and Wallace J.C. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252 (1998) 368-372
39. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 (1990) 1107-1112
40. Sulavik M.C., Houseweart C., Cramer C., Jiwani N., Murgolo N., Greene J., et al. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother 45 (2001) 1126-1136
41. Mayer K.M., and Arnold F.H. A colorimetric assay to quantify dehydrogenase activity in crude cell lysates. J Biomol Screen 7 (2002) 135-140
42. Zenno S., Koike H., Tanokura M., and Saigo K. Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. J Biochem (Tokyo) 120 (1996) 736-744
43. Zenno S., Koike H., Kumar A.N., Jayaraman R., Tanokura M., and Saigo K. Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol 178 (1996) 4508-4514
44. Nakanishi M., Yatome C., Ishida N., and Kitade Y. Putative ACP phosphodiesterase gene (acpD) encodes an azoreductase. J Biol Chem 276 (2001) 46394-46399
45. Helsby N.A., Ferry D.M., Patterson A.V., Pullen S.M., and Wilson W.R. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 90 (2004) 1084-1092
46. Knox R.J., Friedlos F., Sherwood R.F., Melton R.G., and Anlezark G.M. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 44 (1992) 2297-2301
47. Knox R.J., Friedlos F., Marchbank T., and Roberts J.J. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol 42 (1991) 1691-1697
48. Roschke A.V., Stover K., Tonon G., Schaffer A.A., and Kirsch I.R. Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability. Neoplasia 4 (2002) 19-31
49. Wilson W.R., Pullen S.M., Hogg A., Helsby N.A., Hicks K.O., and Denny W.A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 62 (2002) 1425-1432
50. Klaidman L.K., Leung A.C., and Adams Jr. J.D. High-performance liquid chromatography analysis of oxidized and reduced pyridine dinucleotides in specific brain regions. Anal Biochem 228 (1995) 312-317
51. London J., and Knight M. Concentrations of nicotinamide nucleotide coenzymes in micro-organisms. J Gen Microbiol 44 (1966) 241-254
52. Yu Q., and Heikal A.A. Two-photon autofluorescence dynamics imaging reveals sensitivity of intracellular NADH concentration and conformation to cell physiology at the single-cell level. J Photochem Photobiol B 95 (2009) 46-57
53. Patterson A.V., Ferry D.M., Edmunds S.J., Gu Y., Singleton R.S., Patel K., et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 13 (2007) 3922-3932
54. Oda Y. Induction of SOS responses in Escherichia coli by 5-fluorouracil. Mutat Res 183 (1987) 103-108
55. Barak Y., Nov Y., Ackerley D.F., and Matin A. Enzyme improvement in the absence of structural knowledge: a novel statistical approach. ISME J 2 (2008) 171-179
56. Gonzalez-Perez M.M., van Dillewijn P., Wittich R.M., and Ramos J.L. Escherichia coli has multiple enzymes that attack TNT and release nitrogen for growth. Environ Microbiol 9 (2007) 1535-1540
57. Jorgensen M.A., Trend M.A., Hazell S.L., and Mendz G.L. Potential involvement of several nitroreductases in metronidazole resistance in Helicobacter pylori. Arch Biochem Biophys 392 (2001) 180-191
58. Adams M.A., and Jia Z. Modulator of drug activity B from Escherichia coli: crystal structure of a prokaryotic homologue of DT-diaphorase. J Mol Biol 359 (2006) 455-465
59. Carey J., Brynda J., Wolfova J., Grandori R., Gustavsson T., Ettrich R., et al. WrbA bridges bacterial flavodoxins and eukaryotic NAD(P)H:quinone oxidoreductases. Protein Sci 16 (2007) 2301-2305
60. Miller S., Ness L.S., Wood C.M., Fox B.C., and Booth I.R. Identification of an ancillary protein, YabF, required for activity of the KefC glutathione-gated potassium efflux system in Escherichia coli. J Bacteriol 182 (2000) 6536-6540
61. Loh KD, Gyaneshwar P, Markenscoff Papadimitriou E, Fong R, Kim KS, Parales R, et al. A previously undescribed pathway for pyrimidine catabolism. Proc Natl Acad Sci USA 2006;103:5114-9.
62. Choi J.W., Lee J., Nishi K., Kim Y.S., Jung C.H., and Kim J.S. Crystal structure of a minimal nitroreductase, YdjA, from Escherichia coli K12 with and without FMN cofactor. J Mol Biol 377 (2008) 258-267